Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis

Acta Histochemica

Volumn 113, Issue 8, 2011, Pages 833-838

  Lu, Jeng Wei ^a   Chang, Jan Gowth ^b   Yeh, Kun Tu ^c   Chen, Rong Ming ^e   Tsai, Jeffrey J P ^a   Hu, Rouh Mei ^a,d  

^a ASIA UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL UNIVERSITY OF TAINAN   (Taiwan)

Author keywords

Cancer stem cell; CD90; Human hepatocellular carcinoma; Prognosis; Thyl

Indexed keywords

MESSENGER RNA; THY 1 ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SURVIVAL RATE; THY1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, THY-1; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 80855144818     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.01.001     Document Type: Article

References (40)

1. Abeysinghe H.R., Cao Q., Xu J., Pollock S., Veyberman Y., Guckert N.L., et al. THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet Cytogenet 2003, 143:125-132.
2. Abeysinghe H.R., Li L.Q., Guckert N.L., Reeder J., Wang N. THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer. Cancer Genet Cytogenet 2005, 161:151-158.
3. Abeysinghe H.R., Pollock S.J., Guckert N.L., Veyberman Y., Keng P., Halterman M., et al. The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. Cancer Genet Cytogenet 2004, 149:1-10.
4. Akiyama S.K., Olden K., Yamada K.M. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 1995, 14:173-189.
5. Buccisano F., Rossi F.M., Venditti A., Del Poeta G., Cox M.C., Abbruzzese E., et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 2004, 125:203-212.
6. Chen C.J., You S.L., Lin L.H., Hsu W.L., Yang Y.W. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 2002, 32(Suppl.):S66-S81.
7. Cho R.W., Wang X., Diehn M., Shedden K., Chen G.Y., Sherlock G., et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem cells 2008, 26:364-371.
8. Craig W., Kay R., Cutler R.L., Lansdorp P.M. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993, 177:1331-1342.
9. Dan Y.Y., Riehle K.J., Lazaro C., Teoh N., Haque J., Campbell J.S., et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A 2006, 103:9912-9917.
10. Dennis J.E., Esterly K., Awadallah A., Parrish C.R., Poynter G.M., Goltry K.L. Clinical-scale expansion of a mixed population of bone-marrow-derived stem and progenitor cells for potential use in bone-tissue regeneration. Stem Cells 2007, 25:2575-2582.
11. Ding X., Yang L.Y., Huang G.W., Yang J.Q., Liu H.L., Wang W., et al. Role of AFP mRNA expression in peripheral blood as a predictor for postsurgical recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol 2005, 11:2656-2661.
12. El-Serag H.B. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002, 35:S72-S78.
13. Fiegel H.C., Kaifi J.T., Quaas A., Varol E., Krickhahn A., Metzger R., et al. Lack of Thy1 (CD90) expression in neuroblastomas is correlated with impaired survival. Pediatr Surg Int 2008, 24:101-105.
14. Fujita N., Kato Y., Naito M., Tsuruo T. A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. Int J Cancer 1996, 66:544-550.
15. Fujita N., Kodama N., Kato Y., Lee S.H., Tsuruo T. Aggregation of Thy-1 glycoprotein induces thymocyte apoptosis through activation of CPP32-like proteases. Exp Cell Res 1997, 232:400-406.
16. Haeryfar S.M., Hoskin D.W. Thy-1: more than a mouse pan-T cell marker. J Immunol 2004, 173:3581-3588.
17. He H.T., Naquet P., Caillol D., Pierres M. Thy-1 supports adhesion of mouse thymocytes to thymic epithelial cells through a Ca2(+)-independent mechanism. J Exp Med 1991, 173:515-518.
18. Herrera M.B., Bruno S., Buttiglieri S., Tetta C., Gatti S., Deregibus M.C., et al. Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006, 24:2840-2850.
19. Hirohashi S.K., Kojiro M., Puig P.L., Wanless I.R., Fischer H.P., Theise N.D., et al. Hepatocellular carcinoma. Pathology and genetics of tumours of the digestive system 2000, 159-172. IARC Press, Lyon. S.R. Hamilton, L.A. Aaltonen (Eds.).
20. Jeong J.A., Hong S.H., Gang E.J., Ahn C., Hwang S.H., Yang I.H., et al. Differential gene expression profiling of human umbilical cord blood-derived mesenchymal stem cells by DNA microarray. Stem Cells 2005, 23:584-593.
21. Lazaro C.A., Croager E.J., Mitchell C., Campbell J.S., Yu C., Foraker J., et al. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology 2003, 38:1095-1106.
22. Lippincott-Raven P. Digestive system. American joint committee on cancer: AJCC cancer staging manual 2009, Springer, New York, pp. 191-200.
23. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
24. Lu H.C., Chou F.P., Yeh K.T., Chang Y.S., Hsu N.C., Chang J.G. Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. Pathology 2009, 41:626-629.
25. Lu J.W., Chang J.G., Yeh K.T., Chen R.M., Tsai J.J., Hu R.M. Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma. Med Oncol 2010, 10:9707-9709.
26. Lung H.L., Bangarusamy D.K., Xie D., Cheung A.K., Cheng Y., Kumaran M.K., et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 2005, 24:6525-6532.
27. Lung H.L., Cheung A.K., Cheng Y., Kwong F.M., Lo P.H., Law E.W., et al. Functional characterization of THY1 as a tumor suppressor gene with antiinvasive activity in nasopharyngeal carcinoma. Int J Cancer 2010, 127:304-312.
28. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
29. Pascal L.E., Goo Y.A., Vencio R.Z., Page L.S., Chambers A.A., Liebeskind E.S., et al. Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer 2009, 9:317.
30. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
31. Rege T.A., Hagood J.S. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 2006, 20:1045-1054.
32. Saalbach A., Hildebrandt G., Haustein U.F., Anderegg U. The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells. Microvasc Res 2002, 64:86-93.
33. Saalbach A., Wetzel A., Haustein U.F., Sticherling M., Simon J.C., Anderegg U. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 2005, 24:4710-4720.
34. Simonetti R.G., Camma C., Fiorello F., Politi F., D'Amico G., Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991, 36:962-972.
35. Tiveron M.C., Barboni E., Pliego Rivero F.B., Gormley A.M., Seeley P.J., Grosveld F., et al. Selective inhibition of neurite outgrowth on mature astrocytes by Thy-1 glycoprotein. Nature 1992, 355:745-748.
36. Tseng H.H., Hwang Y.H., Yeh K.T., Chang J.G., Chen Y.L., Yu H.S. Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol 2009, 135:241-247.
37. Tung-Ping Poon R., Fan S.T., Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000, 232:10-24.
38. Yamazaki H., Nishida H., Iwata S., Dang N.H., Morimoto C. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun 2009, 383:172-177.
39. Yang Z.F., Ho D.W., Ng M.N., Lau C.K., Yu W.C., Ngai P., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
40. Yeh C.N., Lee W.C., Chen M.F., Tsay P.K. Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol 2003, 10:916-921.